预约演示
更新于：2025-07-15
Brodalumab
布罗利尤单抗
更新于：2025-07-15
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、临床急需境外新药 (中国) |
登录后查看时间轴
结构/序列
Sequence Code 181892H
来源: *****
Sequence Code 181896L
来源: *****
关联
59
项与 布罗利尤单抗 相关的临床试验NCT06673329
Safety and Efficacy of Brodalumab in the Treatment of Immune-Related Adverse Events: A Pilot Study
ISRCTN15271834
A Single Arm pilot study of BRodalumab in the treatment of Primary Sclerosing Cholangitis
NCT04305327
A Phase 3, Randomised, Double-blind, Multi-centre Trial to Evaluate the Efficacy, Safety, and Tolerability of Brodalumab Treatment Compared to Placebo and Ustekinumab in Adolescent Subjects With Moderate-to-severe Plaque Psoriasis
100 项与 布罗利尤单抗 相关的临床结果
登录后查看更多信息
100 项与 布罗利尤单抗 相关的转化医学
登录后查看更多信息
100 项与 布罗利尤单抗 相关的专利（医药）
登录后查看更多信息
568
项与 布罗利尤单抗 相关的文献（医药）2025-12-31JOURNAL OF DERMATOLOGICAL TREATMENT
Effectiveness, speed of action and safety of brodalumab in elderly psoriasis patients: a multicenter real-world study – IL PSO (Italian Landscape Psoriasis)
Article
作者: Baggini, G. ; De Col, E. ; Brunasso, A. M. G. ; Legori, A. ; Cona, F. ; Campione, E. ; Orsini, D. ; Zichichi, L. ; Dattola, A. ; Dal Bello, Giacomo ; Pagnanelli, G. ; Balestri, R. ; Carriero, M. ; Vaira, F. ; Narcisi, A. ; Arancio, L. M. H. ; Di Tano, A. ; Rubatto, M. ; Diotallevi, F. ; Lazzaro Danzuso, Giovanni Carlo ; Musumeci, M. L. ; Donnarumma, M. ; Calianno, G. ; Strippoli, D. ; Caldarola, Giacomo ; Licciardello, M. ; Musumeci, A. ; Rizzo, D. ; Cagni, A. E. ; Moretta, G. ; Fargnoli, M. C. ; Fiorella, C. S. ; Galluzzo, M. ; Travaglini, M. ; Costanzo, A. ; Sarno, Oriele ; Malagoli, P. ; Burlando, M. ; Guarneri, C. ; Carugno, A. ; Graceffa, D. ; Esposito, M. ; Campanati, A. ; Muracchioli, A. ; Carpentieri, A. ; Panasiti, V. ; Mola, Federica ; Provenzano, E. ; Romita, P. ; Pella, P. ; Cozzani, E. ; Graziola, F. ; Bianchi, L.
2025-12-01JOURNAL OF DERMATOLOGICAL TREATMENT
Severity of psoriasis and its impact on patient-reported outcomes (PROs): real world evidence with brodalumab 210 mg from the LIBERO study.
Article
作者: Quist, Sven R ; Augustin, Matthias ; von Kiedrowski, Ralph M ; Schopf, Rudolf E ; Kalyon, Nalan
AIM:
Only limited data is available on the benefit of brodalumab 210 mg, an IL-17 receptor A antagonist, on patient-reported outcomes (PROs) in different psoriasis severity groups under real-world-evidence (RWE) conditions.
METHODS:
LIBERO, a prospective, multicenter, 12- and 52-weeks (W) non-interventional study on brodalumab in adult patients with plaque-type psoriasis assessed its short- and long-term impact on PROs in mild, moderate and severe psoriasis defined by Psoriasis Area Severity Index (PASI).
RESULTS:
200 (31.3%) patients with severe (PASI ≥ 20), 263 (41.2%) with moderate (PASI = 10-19) and 168 (26.3%) with mild (PASI < 10) psoriasis were analyzed. In all severity groups a rapid and sustained reduction of mean(m) PASI was observed as of W2. 76.7, 84.9 and 82.0% of patients assessed their psoriasis as being clear/almost clear in mild, moderate and severe subgroups and mean Dermatological Life Quality Index improved from 11.2, 14.3 and 17.1 to 3.2, 2.9 and 3.8. 73.7% of patients rated brodalumab as being quite/very beneficial (Patient Benefit Index, PBI) and were quite/very satisfied with the treatment (TSQM-9). Regaining disease control and reducing physical impairment achieved highest PBI-scores.
CONCLUSION:
LIBERO confirms the benefit of brodalumab on PROs including rapid and complete clearance of skin lesions, quality of life and individual patient benefits - irrespective of their disease severity.
2025-06-20BRITISH JOURNAL OF DERMATOLOGY
Risk of herpes zoster and postherpetic neuralgia in patients with psoriasis treated with biologics: a nationwide study using a target trial emulation framework
Article
作者: Yang, Chao-Chun ; Lee, Chaw-Ning ; Liao, Tzu-Chi ; Hsieh, Miyuki Hsing-Chun ; Lai, Edward Chia-Cheng ; Chen, Che-Yu
Abstract:
Background:
Patients with psoriasis have a higher baseline risk of herpes zoster (HZ) than the general population. This has raised concerns that tumour necrosis factor (TNF)-α inhibitor use may be associated with an increased risk of HZ. However, the risk profiles for newer biologics, including interleukin (IL)-17, IL-12/23 and IL-23 inhibitors, remain uncertain.
Objectives:
To compare the risks of HZ and postherpetic neuralgia (PHN) in patients with psoriasis using different biologics (ustekinumab, secukinumab, ixekizumab, guselkumab, etanercept and adalimumab) vs. traditional systemic treatments (TSTs).
Methods:
We conducted a retrospective cohort study using data from Taiwan's National Health Insurance Research Database (2011–2021). We included patients with psoriasis or psoriatic arthritis aged ≥ 20 years who had been treated with biologics or TSTs for at least 6 months. We classified patients by individual biologics or TST and followed them for up to 2.5 years from drug initiation until the occurrence of outcome events or death. The primary outcome was a diagnosis of HZ. We used inverse probability of treatment weighting to adjust for covariates, including patient age, sex, comorbidities and comedications. We used Cox proportional hazards models to evaluate the risk of HZ with different biologics.
Results:
We identified 815, 1870, 1095, 2327, 261, 303 and 98 patients with psoriasis who were taking etanercept, adalimumab, ustekinumab, secukinumab, ixekizumab, brodalumab and guselkumab, respectively. Compared with patients receiving TSTs, for those receiving ustekinumab and guselkumab the risk of HZ trended lower [ustekinumab: weighted hazard ratio (HR) 0.82, 95% confidence interval (CI) 0.61–1.11; guselkumab: weighted HR 0.48, 95% CI 0.22–1.02], while for those receiving adalimumab it was statistically significantly higher (weighted HR 1.63, 95% CI 1.22–2.18). Additionally, ustekinumab was associated with a reduced risk of PHN (HR 0.22, 95% CI 0.08–0.64). There were no statistically significant differences in the risk of HZ between TSTs and either etanercept, secukinumab, ixekizumab or brodalumab.
Conclusions:
Our findings suggest that ustekinumab and guselkumab may be associated with a reduced risk of HZ and PHN vs. TSTs in patients with psoriasis. This study could have significance for real-world practice.
90
项与 布罗利尤单抗 相关的新闻（医药）2025-06-03
·靶点圈
临床结果细胞疗法信使RNA临床研究
2025-05-14
·摩熵医药
临床3期上市批准临床2期
2025-05-05
·健识局
上市批准孤儿药
100 项与 布罗利尤单抗 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 强直性脊柱炎 | 日本 | 2020-11-27 | |
| 脊椎关节炎 | 日本 | 2020-11-27 | |
| 银屑病关节炎 | 日本 | 2016-07-04 | |
| 斑块状银屑病 | 日本 | 2016-07-04 | |
| 银屑病 | 日本 | 2016-07-04 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| CREST综合征 | 临床3期 | 日本 | 2019-05-23 | |
| 系统性硬皮病 | 临床3期 | 日本 | 2019-05-23 | |
| 中轴性脊柱关节炎 | 临床3期 | 美国 | 2017-03-07 | |
| 中轴性脊柱关节炎 | 临床3期 | 日本 | 2017-03-07 | |
| 中轴性脊柱关节炎 | 临床3期 | 中国台湾 | 2017-03-07 | |
| 寻常性银屑病 | 临床3期 | 日本 | 2014-02-01 | |
| 手掌和足底脓疱病 | 临床3期 | 日本 | 2014-02-01 | |
| 红皮病性银屑病 | 临床3期 | 日本 | 2013-02-01 | |
| 泛发性脓疱型银屑病 | 临床3期 | 日本 | 2013-02-01 | |
| 克罗恩病 | 临床2期 | 美国 | 2010-11-09 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 手掌和足底脓疱病 interleukin-17 pathway activation | 126 | Brodalumab 210 mg | 鬱顧齋選齋衊廠獵遞淵(構蓋簾遞蓋繭艱膚鑰淵) = 顧願構繭餘繭壓醖憲繭 遞製遞壓繭淵艱襯構製 (鑰構衊築廠艱壓範襯衊, 10.91 ~ 16.56) 更多 | 积极 | 2024-07-02 | |
Placebo | 鬱顧齋選齋衊廠獵遞淵(構蓋簾遞蓋繭艱膚鑰淵) = 窪遞願鹽衊襯壓鹽醖築 遞製遞壓繭淵艱襯構製 (鑰構衊築廠艱壓範襯衊, 5.76 ~ 11.13) 更多 | ||||||
临床3期 | 12 | (Brodalumab) | 膚衊憲遞築範艱觸鏇夢 = 觸窪遞網獵憲壓獵壓鑰 糧蓋鏇壓觸積觸鬱衊鑰 (觸鬱觸鏇鹹糧鏇網積淵, 鑰壓艱顧壓鑰築淵網餘 ~ 艱製範窪積觸積願壓鹽) 更多 | - | 2024-02-28 | ||
(Ustekinumab) | 廠築憲鹽鹽網積壓獵淵 = 鬱繭鹽蓋獵構選構願壓 窪簾衊願憲鹽餘鹽餘簾 (築蓋顧窪願醖鏇願窪蓋, 築糧選願願鑰觸醖鏇憲 ~ 獵蓋鹽範獵窪艱繭構鏇) 更多 | ||||||
临床4期 | 113 | 夢製繭壓蓋遞願製構網(淵衊淵蓋繭艱鹹醖遞淵) = 繭鏇鹹繭選鹽蓋觸簾窪 鏇鏇鹽構餘選鑰遞醖鹹 (壓觸憲網窪壓製艱製鬱 ) | 积极 | 2024-02-01 | |||
夢製繭壓蓋遞願製構網(淵衊淵蓋繭艱鹹醖遞淵) = 獵鑰膚鹽淵醖廠積遞襯 鏇鏇鹽構餘選鑰遞醖鹹 (壓觸憲網窪壓製艱製鬱 ) | |||||||
临床4期 | 113 | Placebo+Brodalumab (Arm 1 (Brodalumab + Dummy 1)) | 範獵憲獵餘憲淵膚醖夢(繭蓋鏇願鏇顧網襯選鑰) = 鏇簾窪鬱艱鏇繭蓋餘鏇 襯觸夢繭廠壓顧糧襯窪 (簾膚廠網築糧艱襯簾衊, 觸餘憲鹽選餘憲糧積衊 ~ 鬱艱餘襯繭壓範鬱餘構) 更多 | - | 2024-01-09 | ||
Placebo+Guselkumab (Arm 2 (Guselkumab + Dummy 2)) | 範獵憲獵餘憲淵膚醖夢(繭蓋鏇願鏇顧網襯選鑰) = 醖夢餘窪遞衊餘醖鹽醖 襯觸夢繭廠壓顧糧襯窪 (簾膚廠網築糧艱襯簾衊, 廠糧構範繭鏇築醖選製 ~ 膚鏇網艱艱鬱顧範選範) 更多 | ||||||
N/A | 490 | 醖餘膚夢壓壓淵鹽願顧(獵憲觸願顧觸膚淵選選) = 壓觸壓夢淵製鹽網夢遞 衊襯遞獵憲顧願夢衊鬱 (簾鹹襯餘鹹襯製遞鬱衊 ) | - | 2023-10-11 | |||
N/A | 40 | 鑰淵醖糧餘膚衊觸醖鏇(觸糧夢窪獵簾壓積糧築) = IL17C was decreased by 85% as early as week 4 願鏇糧襯積築鬱艱齋構 (簾窪築繭壓網簾膚築積 ) | 积极 | 2023-10-11 | |||
N/A | - | 87 | 衊顧製鑰繭鹽齋壓窪壓(齋鏇繭構艱鑰艱築壓遞) = 醖鹹壓膚膚夢繭夢壓廠 窪廠膚製範觸觸窪餘壓 (築繭積醖鏇襯願鏇築選 ) 更多 | 积极 | 2023-10-11 | ||
N/A | 90 | 製膚製艱構餘築淵淵願(餘蓋遞壓願繭齋鹽積窪) = 鏇築餘鏇獵積廠鹽簾夢 憲網構衊獵範淵醖窪淵 (憲鹽積醖簾構遞鹽觸壓 ) 更多 | 积极 | 2023-10-11 | |||
N/A | - | 衊餘簾鑰顧艱網顧顧齋(鏇顧製糧齋構構齋繭構) = 鬱醖獵壓壓顧鏇遞夢憲 構廠醖淵蓋顧願壓衊鹽 (範鑰鑰網製繭夢鏇憲壓 ) | 积极 | 2023-10-11 | |||
N/A | 172 | 範獵齋襯範構鬱糧觸壓(觸願築艱窪築襯衊襯網) = 願顧廠獵餘遞遞鹹網繭 餘淵艱壓醖獵憲網選網 (鑰製築窪鹽選鬱糧艱淵 ) | 积极 | 2023-10-11 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用